Jubilant Therapeutics Inc. annonce le développement d’inhibiteurs de PD-L1 à petite molécule, disponibles par voie orale et pénétrant dans le cerveau, lors de la réunion annuelle 2022 de l’American Society of Clinical Oncology (ASCO) France – Français USA – English Deutschland – Deutsch
Jubilant Therapeutics Inc. berichtet auf der Jahrestagung 2022 der American Society of Clinical Oncology (ASCO) über die Entwicklung oral verfügbarer und ins Gehirn eindringender niedermolekularer PD-L1-Inhibitoren Deutschland – Deutsch USA – English France – Français
Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting
United States Transportation Markets Report 2022: Shared Mobility Services, Public Transit Electrification, Multimodal Connectivity, and Autonomous Mobility to Spur Transformational Growth
National Leaders and Latina Celebrities to Gather at the 2022 Women Entrepreneurs Empowerment Summit in NYC to Succeed!
Vanpowers Bike will Launch the World’s First Electric Bike with an Assembled Frame on Indiegogo, on May 24, 2022, with More Than 10 Customized Colors